Boronic Acids Unbound: Reversible Covalent Chemistry for Responsive Molecular Design

Boronic acids have long been valued for what they enable rather than for what they are. As coupling partners in transition-metal-catalysed bond formation, they are among the most heavily used reagents in synthetic chemistry, prized for stability, low toxicity and tolerance of diverse functional groups. That reputation, however, describes only their role as intermediates. A quite different body of work treats them as the functional element of the final molecule rather than a means of reaching it.

Related Products

What makes this possible is the coordination behaviour of boron itself. The atom interconverts between a neutral, trigonal planar arrangement with a vacant orbital and an anionic, tetrahedral form generated by addition of a nucleophile. Because this interconversion is reversible and responds to conditions such as pH, the presence of diols and the local concentration of thiols, boron provides a covalent linkage that can be formed and broken under mild, physiologically relevant control.

The Coordination Equilibrium at the Centre of the Chemistry

In the trigonal planar state the boron atom is electron-deficient and behaves as a Lewis acid. Interaction with a suitable nucleophile generates a negatively charged tetrahedral adduct, and the position of this equilibrium determines chemical behaviour. Because the tetrahedral form is stabilised at higher pH, and because binding to a diol lowers the effective acidity of the boron centre, the equilibrium can be shifted by changing either the medium or the binding partner.

Fig 1. Interconversion between neutral trigonal and anionic tetrahedral boron. (Antonio JPM, et al. 2025)

The best-known consequence is reversible binding to compounds bearing hydroxyl groups on adjacent or nearby carbon atoms. Formation of a cyclic boronate ester with such diols is rapid, and dissociation is equally rapid when a competing binder is introduced or when the pH falls. This delivers something conventional covalent chemistry cannot: a linkage strong enough to persist under physiological conditions yet capable of dissociating in response to a defined chemical cue. A second consequence is susceptibility to oxidation. Reaction with hydrogen peroxide converts the carbon–boron bond into a carbon–oxygen bond, releasing whatever fragment the boron was attached to and providing a chemically clean trigger for environments where oxidative species are elevated. Reference compounds of this kind fall within the boronic acids and derivatives family widely used in method development.

Structural Families and Their Chemical Triggers

Boronate esters formed with diols represent the simplest chemotype. Their stability depends on the geometry of the binding partner, which allows discrimination between structurally related carbohydrates and provides the basis for saccharide recognition. Complexes with hydroxamate-type ligands offer greater stability under physiological conditions while retaining sensitivity to ligand exchange, giving a more robust yet still reversible connection.

Iminoboronates arise when a boronic acid bearing an adjacent carbonyl group reacts with an amine, with the boron centre stabilising the resulting imine through intramolecular coordination. Reaction with N-terminal cysteine residues is rapid and selective, which has made this chemotype valuable for modifying proteins at defined positions. The same linkage is displaced by thiols, so intracellular glutathione concentration functions as a release trigger. Diazaborines, formed from boronic acids and hydrazine or hydrazide partners, offer greater hydrolytic stability while retaining acid sensitivity, and boronated thiazolidines respond particularly to oxidative conditions.

Considered together, these families form a toolkit in which each architecture is matched to a trigger enriched in a particular biological setting: elevated saccharide concentration, acidic extracellular pH, raised intracellular thiol levels, or an oxidative burst. Selectivity therefore comes from the chemistry itself rather than from an appended targeting moiety, and appropriate ligands and catalysts are required to assemble these structures efficiently.

The synthetic accessibility of these motifs is itself part of their appeal. Aryl and heteroaryl boronic acids are commercially available across a very wide substitution range, and established borylation methodologies allow the boron centre to be installed late in a synthetic sequence. This means that a boron handle can often be added to an existing lead compound without redesigning its core, an important practical consideration in medicinal chemistry programmes. Preparation of more elaborate architectures frequently proceeds on solid support, where solid phase synthesis resins allow iterative assembly and simple purification between steps.

Bioconjugation and Site-Selective Protein Modification

Conventional bioconjugation relies on reactions with lysine or cysteine side chains that are typically irreversible and often poorly selective, since a given residue type usually appears many times across a protein surface. Boron chemistry addresses both limitations. The rapid, selective reaction with N-terminal cysteine gives positional control, and reversibility permits construction of conjugates that release their cargo under defined intracellular conditions.

This has been applied to build modular multivalent constructs in which several targeting or effector units are assembled around a boron centre. Because assembly is reversible, the same platform can be reconfigured without redesigning the underlying synthesis. Related approaches have produced dual-modified conjugates in which two distinct payloads are installed sequentially. The relevance to therapeutic conjugates is direct, since ADC linkers that combine circulatory stability with efficient intracellular release remain a central engineering challenge, and boron-based connections offer a mechanistically distinct route to that behaviour.

Reversibility also enables applications that would be impossible with permanent linkages. Affinity reagents can be released intact after capture rather than eluted under denaturing conditions, preserving the functional integrity of the bound species. Immobilised boron functionality has been used in this way to enrich glycosylated proteins and nucleosides bearing cis-diol groups, and the same principle supports reversible attachment of biomolecules to surfaces where recovery matters as much as capture. Comparable strategies underpin several bioconjugation reagents and kits developed for analytical enrichment.

Sensing, Materials and Delivery Systems

Diol recognition provides the foundation for saccharide sensing. Coupling the binding event to an optical or electrochemical readout produces sensors that report on carbohydrate concentration without requiring an enzyme, avoiding the stability constraints that limit enzymatic devices. Boron-functionalised recognition elements can be immobilised on transducer surfaces to construct biosensors for continuous monitoring, and the same recognition chemistry supports affinity separation of glycosylated species in glycan analysis workflows.

In materials chemistry, boronate ester crosslinks generate networks that are covalently connected yet dynamically exchanging. Such hydrogels self-heal after mechanical disruption, flow under shear and reform at rest, making them injectable, and disassemble in response to changes in pH or the presence of competing diols. These properties suit applications in tissue engineering and controlled release, and analogous crosslinking has been applied to electrospun fibres for wound dressings. Incorporating boron functionality into monomers and biomedical polymers extends the same logic to a wide range of formats.

In delivery, oxidation-responsive boronate linkages have been used to release cargo selectively in tissue where reactive oxygen species are elevated, a condition characteristic of inflamed and malignant tissue. Boron-functionalised nanoparticles and liposomes exploit this to achieve environment-dependent release, and photosensitiser conjugates have been designed so that photodynamic activity is unmasked only after a specific chemical trigger.

Separation science has adopted the same recognition chemistry at preparative scale. Boron-functionalised stationary phases retain cis-diol-containing analytes at elevated pH and release them on acidification, providing an orthogonal selectivity that complements conventional reversed-phase and ion-exchange approaches. This has proved particularly useful for enriching glycated haemoglobin, nucleosides and glycopeptides from complex matrices ahead of analysis, and equivalent chemistry has been immobilised on ion exchange resins and membrane formats where throughput matters more than resolution.

Boron-Containing Therapeutics

Several boron-containing compounds have progressed to approved clinical use, providing the clearest validation of boron as a pharmacophore rather than a synthetic convenience. Proteasome inhibitors exploit the ability of the boron centre to form a reversible covalent adduct with the catalytic threonine residue of the proteasome, producing potent inhibition that is nonetheless reversible on dissociation. Antifungal and antibacterial agents employ boron to engage editing sites in aminoacyl-tRNA synthetases or to inhibit bacterial enzymes conferring resistance to established antibiotics. A phosphodiesterase inhibitor used topically for inflammatory skin disease follows similar logic.

Across these examples the common feature is transition-state mimicry: the tetrahedral boronate resembles the tetrahedral intermediate formed during enzymatic catalysis, generating high affinity for the active site while retaining reversibility. This distinguishes boron-based inhibitors from irreversible covalent agents, where permanent modification of the target carries a different toxicological profile.

Simple boron compounds have themselves attracted renewed attention. Boric acid and related species display antioxidant, anti-inflammatory, antimicrobial and osteoprotective activity in preclinical models, with mechanisms attributed to reversible complexation with cis-diol-containing biomolecules and to consequent effects on cofactor availability and inflammatory signalling. Boron neutron capture therapy pursues an entirely different route, using selective accumulation of a boron isotope in tumour tissue followed by neutron irradiation. Toxicological evaluation of these compounds relies on established genotoxicity assay kits and in vitro ADME products to characterise safety margins early.

Agricultural and antimicrobial chemistry has followed a parallel path. Boron-containing agents that inhibit editing domains of aminoacyl-tRNA synthetases have been developed against fungal plant pathogens, and structural work has confirmed that the mode of binding mirrors that seen in the human antifungal agents. Because this mechanism differs from those of established fungicide classes, cross-resistance is unlikely, which is an attractive property given the pace at which resistance emerges. Screening campaigns of this kind draw heavily on curated collections of chemical building blocks and on high throughput screening assay kits capable of profiling large numbers of analogues efficiently.

Practical Considerations and Outstanding Challenges

Several constraints temper enthusiasm. The pH at which the trigonal-to-tetrahedral transition occurs for simple arylboronic acids sits above physiological pH, meaning that only a fraction of molecules occupy the binding-competent form under biological conditions. Structural modification, particularly the introduction of ortho substituents capable of intramolecular coordination, lowers this threshold and improves binding, and much of the medicinal chemistry effort in this area has been directed at exactly this problem.

Selectivity presents a second challenge. Diol-containing species are abundant in biological fluids, so a sensor or delivery system relying on diol binding must discriminate its intended target from a large background of structurally similar molecules. Multivalent presentation and geometrically constrained binding pockets both help. Stability is a third consideration: boronic acids can undergo protodeboronation or oxidative degradation during storage and handling, so appropriate solvents and buffers and reagents matter for reproducibility, and purification often benefits from scavenger resins that remove boron-containing impurities.

Analytical characterisation presents its own difficulties. Boron has two naturally occurring isotopes, which produces a distinctive but sometimes inconvenient pattern in mass spectra, and the exchangeable hydroxyl protons complicate nuclear magnetic resonance interpretation in protic solvents. Boron-specific spectroscopy resolves much of this ambiguity, and elemental analysis provides independent confirmation of boron content. For biological samples, quantification of total boron alongside speciation of the intact molecule is often necessary, since the two answer different questions and the reference materials required for each differ accordingly.

Conclusion

The distinguishing feature of boron chemistry is not exceptional reactivity but exceptional controllability. Interconversion between two well-defined geometries, each with distinct electronic character, gives access to covalent linkages that form rapidly under mild conditions and dissociate in response to chemical cues that differ measurably between healthy and diseased tissue. That combination is difficult to achieve with any other element in the organic chemist's ordinary repertoire.

The practical consequences already extend across approved therapeutics, self-healing materials, enzyme-free sensors and stimulus-responsive delivery systems. As the mechanistic picture becomes more quantitative and as synthetic access to more elaborate architectures improves, boron seems likely to move further from the periphery of medicinal chemistry toward a settled place among the structural motifs routinely considered during molecular design.